Nautilus Biotechnology (NAUT) Accounts Payables (2020 - 2026)

Nautilus Biotechnology has disclosed Accounts Payables across 7 years of filings, most recently posting $1.2 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.2 million, up 41.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 41.02% YoY), and the FY2025 annual result was $943000.0, down 4.46% from the prior year.
• Accounts Payables came in at $1.2 million for Q1 2026 at Nautilus Biotechnology, up from $943000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.9 million in Q1 2024 to a low of $823000.0 in Q3 2022.
• The 5-year median for Accounts Payables is $1.2 million (2023), against an average of $1.2 million.
• Across the five-year window, Accounts Payables surged 1172.82% in 2022 and plunged 54.78% in 2025, its largest moves.
• Nautilus Biotechnology's Accounts Payables stood at $1.3 million in 2022, then advanced by 28.85% to $1.6 million in 2023, then slumped by 39.78% to $987000.0 in 2024, then dropped by 4.46% to $943000.0 in 2025, then grew by 25.77% to $1.2 million in 2026.
• The last three Accounts Payables figures came in at $1.2 million (Q1 2026), $943000.0 (Q4 2025), and $893000.0 (Q3 2025), per Business Quant data.